Trial confirms excess cancer risk with tofacitinib

A safety trial was mandated after clinicians noted an increased incidence among patients
Reuters Health
Lymphoma cancer cell

Use of tofacitinib for rheumatoid arthritis increases the risk of developing cancer by almost 50% compared with therapy with a TNF inhibitor, according to a US safety analysis.

The findings have already prompted the Food and Drug Administration to add a ‘black box’ warning on tofacitinib, as well as two other Janus kinase (JAK) inhibitors.